Agrylin and Cor pulmonale chronic - a phase IV clinical study of FDA data

Summary:

Cor pulmonale chronic is reported as a side effect among people who take Agrylin (anagrelide hydrochloride), especially for people who are female, 50-59 old, also take Flexeril, and have Osteoporosis.

The phase IV clinical study analyzes which people have Cor pulmonale chronic when taking Agrylin. It is created by eHealthMe based on reports of 1,248 people who have side effects when taking Agrylin from the FDA, and is updated regularly.

What is Agrylin?

Agrylin has active ingredients of anagrelide hydrochloride. It is often used in primary thrombocythemia. eHealthMe is studying from 1,256 Agrylin users. Check the latest studies of Agrylin.

What is Cor pulmonale chronic?

Cor pulmonale chronic (long lasting enlargement of the right ventricle of the heart) is found to be associated with 146 drugs and 120 conditions by eHealthMe. Check the latest studies of Cor pulmonale chronic.

On Jul, 06, 2026

1,248 people reported to have side effects when taking Agrylin.
Among them, 15 people (1.2%) have Cor pulmonale chronic.

Could Agrylin cause Cor pulmonale chronic?

Among these 15 people:

What is the gender of people who have Cor pulmonale chronic when taking Agrylin? *

female: 100 %
male: 0.0 %

What is the age of people who have Cor pulmonale chronic when taking Agrylin? *

What are other drugs people take besides Agrylin? *

What are other side effects people have besides Cor pulmonale chronic? *

Wound Infection Staphylococcal: 15 people, 100.00%
Wegener's Granulomatosis (inflammation of the blood vessels lungs sinuses): 15 people, 100.00%
Joint Dislocation (a joint position is changed from normal position): 15 people, 100.00%
Lumbar Spinal Stenosis (a medical condition in which the spinal canal narrows and compresses the spinal cord and nerves at the level of the lumbar bone): 15 people, 100.00%
Lung Disorder (lung disease): 15 people, 100.00%
Malocclusion (a misalignment): 15 people, 100.00%
Metastatic Neoplasm (spreadable cancer tumour): 15 people, 100.00%
Bone Erosion: 15 people, 100.00%
Mouth Ulcers: 15 people, 100.00%
Oedema Peripheral (superficial swelling): 15 people, 100.00%

What are the existing conditions these people have? *

Systemic Lupus Erythematosus (an autoimmune disease, which means the body's immune system mistakenly, attacks healthy tissue): 15 people, 100.00%
Osteoporosis (bones weak and more likely to break): 15 people, 100.00%
Thrombocytopenia (decrease of platelets in blood): 11 people, 73.33%

* Approximation only. Some reports may have incomplete information.

Do you take Agrylin and have Cor pulmonale chronic?

- Check whether Cor pulmonale chronic is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Agrylin:

Agrylin (1,256 reports)

Browse all side effects of Agrylin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Cor pulmonale chronic:

Cor pulmonale chronic (146 drugs)

Browse all the conditions that are associated with Cor pulmonale chronic:

Cor pulmonale chronic (120 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on anagrelide hydrochloride (the active ingredients of Agrylin) and Agrylin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.